International Edition
Latest News
Health

Insurers Delay Pediatric Biologic Approvals by Over a Month

Prior Authorization Delays Insurers take more than a month on average to approve biologic drugs prescribed for children with severe asthma and allergies, according to data presented at the American College of Allergy, Asthma and Immunology Annual Scientific…

Insurers Delay Pediatric Biologic Approvals by Over a Month

Prior Authorization Delays

Insurers take more than a month on average to approve biologic drugs prescribed for children with severe asthma and allergies, according to data presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting in Phoenix, Arizona.

Nearly 4 in 10 prior authorization requests for these specialized treatments face outright rejections. Investigators reviewed 326 biologic prescriptions written by allergists at a tertiary care pediatric center in Kansas City, Missouri, between 2018 and 2026.

The study analyzed pediatric patients with a median age of 11.4 years who suffered from uncontrolled asthma, atopic dermatitis, chronic urticaria, or IgE-mediated food allergy. Biologics evaluated in the cohort included omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab. Omalizumab accounted for 182 prescriptions, representing 55.8% of the total, while dupilumab made up 85 prescriptions, or 26.0%.

“When a child’s asthma or allergies are out of control, every week counts,” said Aarti Pandya, MD, a study co-author and ACAAI member.

Pandya said that physicians and families have already agreed on a treatment plan by the time a biologic gets prescribed. Lengthy administrative hurdles expose vulnerable children to severe health risks.

Denial Reasons and Approval Times

Overall, 93.6% of the reviewed prescriptions required prior authorization. Out of those requests, 39.3% were denied by insurance providers.

Insurers cited a failure to meet specific clinical criteria in 24.4% of denials, and enforced a requirement to first try prerequisite medications in 23.4% of cases. For the prescriptions that ultimately cleared the administrative process, the mean interval from the initial write-date to final approval reached 32.65 days.

Pediatric Biologic Access FAQ

Which biologic drugs were included in the Kansas City study?

The retrospective analysis evaluated five specific agents prescribed between 2018 and 2026. These included omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab.

What were the main reasons insurers rejected prior authorization requests?

The most common grounds for denial were failing to meet strict insurer criteria at 24.4% and mandates requiring patients to try prerequisite medications first at 23.4%.

How long did the approval process take for successful prescriptions?

The mean interval from the date a physician wrote the prescription to the date insurance granted approval was 32.65 days.

About the author: Health Desk

Health Desk at Archynewsy.